IE
DNLI icon

Israel Englander’s Denali Therapeutics DNLI Stock Holding History

Israel Englander’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,000
Closed -$288K – 5973
2026
Q1 		$288K Buy
+15,000
New +$298K ﹤0.01% 5024
2021
Q3 		– Sell
-52,300
Closed -$4.1M – 6867
2021
Q2 		$4.1M Sell
52,300
-12,700
-20% -$786K ﹤0.01% 3024
2021
Q1 		$3.71M Buy
65,000
+15,000
+30% +$1M ﹤0.01% 2910
2020
Q4 		$4.19M Buy
+50,000
New +$3.02M ﹤0.01% 2614

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's DNLI Position: Q2 2026 in Review

Israel Englander reduced its Denali Therapeutics (DNLI) stake by 11% in Q2 2026, selling an estimated $2.72M and leaving 1,125,748 shares worth $29M. The position accounts for 0.01% of the portfolio, ranked #1293.

Israel Englander first reported a position in DNLI in Q4 2017 and has held it in 27 quarters since. 290 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Israel Englander held 1,125,748 shares of Denali Therapeutics worth $29M as of Q2 2026.
  • Israel Englander sold 132,202 Denali Therapeutics shares in Q2 2026, an estimated $2.72M.
  • Denali Therapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1293 holding.
  • Israel Englander first reported a position in Denali Therapeutics in Q4 2017 and has held it in 27 quarters since.
  • 290 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.